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ABSTRACT Antibody drug conjugates (ADCs) are an emerg-
ing new class of targeted therapeutics for cancer that use antibod-
ies to deliver cytotoxic drugs to cancer cells. There are two FDA
approved ADCs on the market and over 30 ADCs in the clinical
pipeline against a number of different cancer types. The structure
of an ADC is very complex with multiple components and
considerable efforts are ongoing to determine the attributes nec-
essary for clinical success. Understanding the pharmacokinetics of
an ADC and how it impacts efficacy and toxicity is a critical part of
optimizing ADC design and delivery i.e., dose and schedule. This
review discusses the pharmacokinetic considerations for an ADC
and tools and strategies that can be used to evaluate molecules at
the preclinical stage.
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INTRODUCTION
Antibody drug conjugates (ADCs) are a promising class of
antibody related therapeutics for cancer that combine the
antigen targeting specificity and favorable pharmacokinetic
properties of monoclonal antibodies with the cytotoxic poten-
tial of small molecule chemotherapeutics (1–3). The vision of
ADCs is to provide targeted delivery of the cytotoxic agent to
tumor tissue and spare normal tissue, thereby decreasing its
toxicity and improving its therapeutic window. The design of
an ADC is critical in delivering on this vision and there is a lot
of research focused on the optimal design of the molecule and
its main components i.e., the antibody directed to an antigenic
target, the cytotoxic drug and the linker that attaches the
antibody to the drug (4–6). Some considerations for each
component (antibody, linker, drug) as well as the molecule as
a whole are highlighted in Fig. 1. An important question in the
development of ADCs is to define the exposure-response
relationship for both efficacy and safety. Understanding the
pharmacokinetics of the ADC, exposure at the site of action
and drivers of efficacy and toxicity are important to address
this key question, to further enable the design of a better
molecule. Additionally, this can be used for optimizing dose
and regimen to help realize the promise of an ADC
therapeutic.
Mylotarg® (gemtuzumab ozogamicin) was the first ADC
to be approved in 2000 for the treatment of acute myeloid
leukemia (AML) and was composed of a CD33-targeted an-
tibody linked to the cytotoxic drug calicheamicin via an acid-
labile hydrazone linker. It was later withdrawn from the
market in 2010 over concerns of safety and failure to repro-
duce its clinical benefit. There are currently two FDA ap-
proved ADCs on the market, Adcetris® (brentuximab
vedotin) approved in 2011 for the treatment of Hodgkin’s
Lymphoma and anaplastic large-cell lymphoma, and
Kadcyla® (ado-trastuzumab emtansine) approved in 2013
for the treatment of HER+ metastatic breast cancer.
Adcetris® is a CD30-targeted antibody linked to an auristatin
(monomethyl auristatin E, MMAE) via a protease cleavable
linker, and Kadcyla® is a HER2-targeted antibody
(trastuzumab) linked to a maytansinoid derivative (DM1) via
a non-cleavable thioether linker.
The clinical pipeline has more than 30 ADCs at various
stages of development from Phase 1 to Phase 3 and many
more ADCs at the preclinical stage (7,8). The field is rapidly
evolving and tremendous effort is being put into applying
insights from more advanced ADCs to guide the design of
next generation ADCs. Some of the modifications being ex-
plored include novel cytotoxins, linkers, different sites of con-
jugation, and antibodies to novel antigenic targets. Several
design features of an ADC impact its pharmacokinetics that
A. V. Kamath (*) : S. Iyer
Department of Preclinical and Translational Pharmacokinetics and
Pharmacodynamics, Genentech, Inc, 1 DNAWay (Mailstop 463A)
South San Francisco, CA 94080, USA
e-mail: kamath.amrita@gene.com
Pharm Res (2015) 32:3470–3479
DOI 10.1007/s11095-014-1584-z
could then impact its efficacy and toxicity (5,9). One impor-
tant example is the choice of linker which ideally should be
stable in circulation, but release the active drug inside the
tumor cell. The types of linkers being explored are cleavable
or non-cleavable, with varying degrees of stability. The site of
conjugation on the antibody also has an impact on stability of
the linker with different sites conferring varying degrees of
stability to the ADC.
In this review we discuss the pharmacokinetic consider-
ations in the development of ADCs and the strategies and
tools that can be employed to evaluate them at the preclinical
stage. We also briefly discuss the bioanalytical considerations
and commonly used methods for pharmacokinetic assays.
BIOANALYTICAL CONSIDERATIONS
In addition to being complex molecules, ADCs are also het-
erogeneous mixtures comprising of multiple species with vary-
ing numbers of drugs per antibody (drug to antibody ratio,
DAR) as well as different sites of drug linkage arising from
different conjugation chemistry approaches such as conjuga-
tion through lysines (Kadcyla®) or cysteines derived from
reduced internal disulfide bonds (Adcetris®), or site specific
conjugation (10). These heterogeneous and dynamic charac-
teristics of an ADC result in a unique set of bioanalytical
challenges requiring multiple bioanalytical assays. In order
to adequately characterize the pharmacokinetics of an ADC,
and answer the key question on exposure-response relation-
ships, it is critical to understand what analytes are relevant,
what needs to bemeasured, and at what stage of development.
The bionalytical strategies for the development of ADCs have
been the subject of intense discussion and are highlighted in
several recent papers including a comprehensive review by
Kaur and colleagues at Genentech and a white paper by the
ADC working group of the American Association of Pharma-
ceutical Scientists (11–13).
The analytes commonly used for evaluation of ADC PK
and their associated PK profiles are shown in Fig. 2 (9,11).
They include antibody related analytes such as i) total anti-
body (Tab) which measures both conjugated and unconjugat-
ed antibody and ii) conjugated antibody which measures
antibody that has at least one drug attached to it (i.e.,
≥DAR1), and small molecule related analytes such as i) anti-
body conjugated drug which measures any drug associated
with the antibody and ii) unconjugated drug. The analytical
methods used tomeasure these analytes include ELISA as well
as LC/MS/MS methods.
Additional complexity is introduced by in vivo biotransfor-
mation of an ADC due to deconjugation and catabolism. This
results in changing of the initial DAR distribution caused by
loss of one or more drugs, as well as formation of several new
species such as catabolites and metabolites, linkers and linker
drugs, adducts with endogenous molecules such as albumin,
cysteine, and complexes with any soluble/shed target antigen
and other antibodies (11). Since the DAR distribution can
continue to change in vivo, with possible impact to the clear-
ance, distribution, and activity of the ADC, it is important to
develop appropriate methods to measure this. Novel
bioanalytical assays have been developed to characterize
DAR distribution such as affinity capture capillary LC-MS
and affinity capture hydrophobic interaction chromatography
(HIC) (11,14–16). In addition to DAR distribution, these
assays can also provide insights into the mechanisms of drug
loss e.g., maleimide exchange and formation of adducts with
albumin or cysteine for ADCs using maleimide chemistry
(11,17).
At the preclinical stage, when the ADC design is still being
optimized, it is valuable to use all these assays to characterize
the pharmacokinetics as well as gain a mechanistic
Fig. 1 Desired attributes of the
components of an ADC.
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understanding of deconjugation and catabolism processes.
With further development and availability of more informa-
tion on the mechanisms of biotransformation, exposure-
response relationships, as well as the correlation between
various analytes, the types of bioanalytical assays employed
could be determined on a case-by case basis depending on the
type of information required at that stage (13).
PHARMACOKINETIC PROPERTIES OF ADCS
The primary mechanism of action of an ADC is binding to its
specific antigen target on tumor cells and internalization via
receptor mediated endocytosis followed by trafficking from
endosomes to the lysosomes where the cytoxic drug is released
into the cell causing cell death (1). The ADC however can also
be taken up into cells (with or without target expression) non-
specifically via pinocytosis, which could lead to unwanted
drug release in non-target cells. Such non-specific uptake
and release of potent drug could contribute to toxicity. The
theoretical ADC elimination pathways based on nonclinical
and clinical data are shown in Fig. 3 and include
deconjugation and degradation or catabolism through non-
specific or target-mediated proteolysis (9). These processes
could take place to varying extents in circulation and/or
intracellularly depending on the characteristics of the ADC
components (5,17,18). Deconjugation of the ADC leads to the
formation of unconjugated antibody and unconjugated drug,
while catabolism of the ADC leads to the formation of anti-
body fragments or drug containing catabolites. The unconju-
gated antibody or antibody fragments can further undergo
proteolysis to generate/release amino acids. The cytotoxic
drug and drug related catabolites can undergo metabolism
via CYP or non-CYP enzymes or be transported by
transporters like P-gycoprotein and get excreted via the biliary
or renal route.
The overall PK characteristics of an ADC such as slow
clearance, long half-life and limited tissue distribution are
driven by its antibody component. In addition to the antibody
component, there are additional elimination mechanisms re-
lated to its linker and drug component. The characteristics of
an ADC that can influence its pharmacokinetics and factors
that should be considered during its preclinical development
are shown in Table I and are discussed in more detail below.
The PK parameters with the conjugated antibody analyte of
Adcetris® and Kadcyla® across multiple species are shown in
Table II.
Antibody
Characteristics related to antibody biology that affect the PK
of an ADC include antibody structure, binding affinity and
specificity to the antigen, FcRn binding, and Fcgamma inter-
action that drive effector functions (23,24). The relatively long
life of an ADC compared to a small molecule is due to
recycling via FcRn, which protects it from catabolism in the
lysosomes. As with antibodies, the ADC can be taken up into
cells specifically via receptor mediated endocytosis (target-
dependent mechanism) or non-specifically via pinocyctosis
(target-independent mechanism). FcRn-bound ADC can be
recycled back to the cell surface and released back into circu-
lation while ADC that is not bound to FcRn undergoes
proteolytic degradation in the lysosome. Another similarity
of ADCs to antibodies is the phenomenon of target mediated
drug disposition where the interaction of the antibody with the
target antigen impacts its pharmacokinetics including its clear-
ance and distribution (25). This typically results in non-linear
PK with higher clearance at lower doses and a decrease in the
clearance at higher doses once the target is saturated. Also
Fig. 2 Pharmacokinetic profiles of
different analytes.
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similar to an antibody, the tissue distribution of an ADC is
limited with the initial distribution in the vascular space
followed by slow diffusion across vascular endothelial cells into
tissues. This can also be influenced by binding to and inter-
nalization by the target antigen (23,24). Other factors that
impact PK and tissue distribution of an ADC that are similar
to an antibody are i) presence of soluble and/or shed antigen
in circulation that can form immune complexes on binding to
the ADC (26,27), and ii) immunogenicity to the ADC (forma-
tion of anti-therapeutic antibodies, ATAs) that can increase its
clearance and decrease exposure (24).
The selection of the right antibody that has pharma-
cokinetic properties that are consistent with expected
IgG behavior is very crucial to ensure optimal PK
properties of the ADC. The pharmacokinetics of an
antibody may be altered by the conjugation of the drug
(28) and this impact can be discerned by comparing the
PK profiles of the naked antibody and the Tab of the
ADC as shown in Fig. 4. The further apart the two
curves, the larger is the impact of conjugation on the
antibody. Conjugation can also impact the tissue distri-
bution as has been observed for some ADCs when
compared to the naked antibody (29,30). Several factors
that could contribute to this change including drug
load, hydrophobicity among others have been investigat-
ed and are discussed in more detail below.
Fig. 3 Proposed disposition of an
ADC.




Antibody PK of naked antibody should be consistent with expected
IgG PK (non-target mediated disposition)
Characterize PK-dose dependency: target affinity, target
expression/turnover, no off-target binding
Linker i) Conjugation can impact the PK of an antibody depending on
the type of conjugation chemistry utilized.
ii) Linker should have suitable stability to deliver ADC to target to
minimize toxicity but have sufficient lability to release active drug once
internalized
i) Assess impact of conjugation of the PK of the naked antibody
ii) Assess linker stability in vitro and in vivo
iii) Evaluate what is being released (active drug, catabolites)
iv) Evaluate mechanism for instability across species
Site of
conjugation
Conjugation at some sites stabilizes the linker possibly due
to differences in solvent accessibility and local charge.
Assess linker stability in vitro and in vivo.
Drug load
(DAR)
Higher DAR species associated with faster clearance and increased
toxicity
Assess in vivo pharmacokinetics and tissue distribution
Cytotoxic drug i) MOA of the drug can impact the PK driver of efficacy/toxicity
e.g. tubulin binding agents vs. DNA damaging agents
ii) Release of the active drug and any relevant metabolites could
also impact PK drivers
i) Assess metabolites, DDI potential (CYP inhibition/ induction/
reaction phenotyping)
ii) P-gp substrate/inhibitor (other transporters)
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Linker
An important consideration impacting the pharmacokinetics
of an ADC is the stability of linker. Ideally the linker should be
stable in circulation to minimize toxicity but release the active
cytotoxin once it is internalized by the tumor cell. The linkers
can be categorized as cleavable and non-cleavable, with vary-
ing degrees of stability (1,31). Cleavable linkers use mecha-
nisms within the cells or cellular compartments to release
active cytotoxin, such as low pH (acid labile linkers), glutathi-
one levels (disulfide linkers), and lysosomal proteases (protease
cleavable linkers). In contrast, for non-cleavable linkers (e.g.
thioether linkers), the entire ADC has to be degraded to
release the active cytotoxin. The three advanced ADCs all
use different linker types (1,31): peptide based protease cleav-
able linker (Adcetris®, linker: MC-vc-PAB), non-cleavable
thioether linker (Kadcyla®, linker: MCC), and acid-labile
hydrazone linker (Mylotarg®, linker: AcBut). The comparison
of the Tab profile with the conjugated antibody profile allows
for an assessment of linker stability as shown conceptually in
Fig. 5, where the conjugated antibody concentrations for the
more unstable linker decline much faster compared to that of
the stable linker.
Different types of linkers used on the same antibody can
impact its pharmacokinetics as illustrated by the following
examples. The pharmacokinetics of anti-HER2 ADCs was
determined in mice using disulfide linkers with different hin-
dered structures (32). The clearance of the ADC decreased
with the increase in the degree of hindrance of the disulfide
linker as follows: SPDP-DM1 (least hindered) > SPP-DM1 >
SSNPP-DM3 > SSNPP-DM4 (most hindered). The MCC-
DM1 linker (nonreducible thioether) had similar pharmaco-
kinetics in this study as the SSNPP-DM4 (most hindered
disulfide). Similar results were seen in other studies where
the pharmacokinetics of a disulfide linker (SPP) was compared
to a thioether linker (MCC) linking the cytotoxic drug DM1 to
two different antibodies, anti-CD22 and anti-HER2 in rats
and mice, respectively (33,34). The Tab clearance for each of
the antibody was similar regardless of the linker, however the
ADC clearance (i.e., conjugated antibody clearance) was
faster for SPP-DM1 compared to MCC-DM1, for both anti-
CD22 and anti-HER2 ADCs as shown in Table III. Another
interesting observation was different metabolite profiles for
different linker types, with the cleavable linkers releasing cy-
totoxic drug, and the non-cleavable linkers releasing the drug
attached to an amino acid: e.g., maytansinoid ADCs with the
non-cleavable linkerMCC-DM1 produced only lysine-MCC-
DM1 whereas ADCs with cleavable linkers SPP-DM1 and
SPDB-DM4 produced multiple metabolites including lysine-
SPP-DM1, DM1, S-methyl-DM1, S-methyl-DM1-sulfoxide
and S-methyl-DM1-sulfone (for mAb-SPP-DM1), and ly-
sine-SPDB-DM4, DM4, S-methyl-DM4, S-methyl-DM4-
Table II ADC Pharmacokinetic parameters of Kadcyla® and Adcetris® in
Rat, Monkey, and Human
Characteristic Kadcyla® Adcetris®
Target HER2 CD30
Antibody isotype IgG1 IgG1
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a Human PK parameters from Phase 1 studies in Cycle 1 at doses at or near
MTD
Fig. 4 Effect of conjugation on the PK profile of an antibody. Fig. 5 PK profiles of ADCs with different linker stability.
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sulfoxide and S-methyl-DM4-sulfone (for mAB-SPDB-DM4)
(35). Some of these metabolites could also enhance anti-tumor
activity via bystander killing mechanisms where the cytotoxic
agent released in one cell diffuses to neighboring cells and
exerts its effect (34,35).
As highlighted in these examples, during optimization of an
ADC, the linker type needs to be carefully evaluated with
regard to its stability, impact on catabolism, and how that
affects its pharmacokinetics.
Cytotoxic Drug
While the cytotoxic drug does not drive the PK of the ADC per
se, its MOA can impact the PK drivers of efficacy and toxicity.
The two main categories of cytotoxins currently being ex-
plored are microtubule inhibitors (auristatins, maytansinoids)
and DNA damaging agents (calicheamicin, duocarmycins,
anthracyclines, pyrrolobenzodiazepine dimers). Unlike micro-
tubule inhibitors that preferentially kill proliferating cells, DNA
damaging agents can also kill non-proliferating cells, potential-
ly giving them a different spectrum of efficacy as well as
toxicity. This could play a role in changing the PK driver of
efficacy as well as toxicity and emphasizes the importance of
investigating appropriate dosing regimens to optimize efficacy
andminimize toxicity depending on the type of cytotoxin used.
The three most advanced ADCs use different cytotoxins:
calicheamicin (Mylotarg®), auristatin (MMAE, Adcetris®),
and maytansinoid (DM1, Kadcyla®). Most of the ADCs in
the clinical pipeline also use these three types of cytotoxins:
calicheamicin, DM1, DM4, MMAE (7). SG-CD33A, a novel
CD33 targeting ADC with a pyrolobenzodiapine dimer and
using site specific conjugation with engineered cysteines has
recently entered Phase 1 trials in AML patients and it will be
interesting to see the pharmacokinetic and safety profiles of this
ADC with a novel cytotoxin and linker (36,37). In addition to
theMOA of these different cytotoxins, molecule characteristics
such as permeability, metabolism, and whether it is a P-
glycoprotein substrate could also play important roles in de-
termining bystander effects and resistance development (1,31).
Drug Load and Site-Specific Conjugation
The conventional processes to conjugate linker-drugs to anti-
bodies (lysine conjugation or conjugation to cysteines derived
from reduction of inert-chain disulfide bonds) produces ADCs
with heterogeneous mixtures of multiple species with different
drug loads: DAR of 0–8 (10).
Each of these DAR species could potentially have distinct
PK properties and activities (28,38). While in vitro potency
could increase with increase in drug load per antibody, it does
not always follow that in vivo efficacy and safety profiles will
also improve (28). Hambelet et al. (28), made ADCs with an
anti-CD30 antibody (cAC10) conjugated to MMAE with the
MC-vc-PAB linker with either two, four, or eight drugs per
antibody. ADCs with lower drug loads (DAR of 2 or 4) had
slower clearance values, longer half-lives and were better
tolerated in mice compared to an ADC with a higher drug
load (DAR of 8). In addition, the DAR4 ADC showed equiv-
alent in vivo antitumor activity to the DAR8 ADC at equal
antibody doses despite having half the amount of MMAE.
Similar results were seen in a rat study with trastuzumab-MC-
vc-PAB-MMAF conjugates (DAR of 2, 4, and 6), where the
ADCS with the higher drug loads cleared faster and were less
tolerated compared to conjugates with lower drug loads (39).
The next generation ADC efforts have focused on elimi-
nating this heterogeneity by using site-specific conjugation
methods to produce a more homogenous ADC to improve
stability, PK, and therapeutic index, as shown in several recent
studies (17,29,40,41). These conjugation strategies include the
use of engineered cysteines, unnatural amino acids, and enzy-
matic conjugation through glucotransfersases and
transglutaminases (10). A recent study at Genentech using
site-specific conjugation with engineered cysteines
(THIOMAB™ technology) showed that chemical and struc-
ture dynamic of the conjugation site can influence the stability
of the ADC (17). Three thio-trastuzumab-MC-vc-MMAE
THIOMABs were generated (DAR of 1.7–1.9) using
engineered cysteines at three different sites (Fc-S396C, LC-
V205C, HC-A114C), differing in solvent accessibility and
Table III Effect of Linker on PK of Tab and Conjugate in Mice (Anti-Her2 ADCs) and Rats (Anti-CD22 ADCs)
Molecule Linker type Tab CL mL/day/kg Conjugate CL mL/day/kg
Anti-HER2 ADC PK in mousea: dose of 3 mg/kg
Trastuzumab-SPP-DM1 Cleavable (disulfide) 8.5 41
Trastuzumab-MCC-DM1 (T-DM1) Non-cleavable 8.4 19
Anti-CD22 ADC PK in rata: dose of 2000 μg/m2 of drug (approximately 20 mg/kg of ADC)
CD22-SPP-DM1 Cleavable (disulfide) 13 67
CD22-MCC-DM1 Non-cleavable 11 18
CD22-MC-MMAF Non-cleavable 11 29
CD22-MC-vc-PAB-MMAE Cleavable (protease) 24 90
a References: (33,34)
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local charge. The conjugate at a highly solvent accessible site
(Fc-S396C) was the most unstable in plasma and allowed
maleimide exchange of the linker drug with reactive thiols in
albumin, free cysteine, or reduced glutathione. Other ADCs
using maleimide chemistry such as anti-CD30-MC-MMAF
and anti-CD70-MC-MMAF have also shown adduct forma-
tion in plasma, such as albumin-MC-MMAF and cys-MC-
MMAF (42,43). The conjugate at a partially accessible site
with a positively charged environment (LC-V205C)
prevented this maleimide exchange by promoting
succinimide ring hydrolysis and was the most stable in
plasma. The stability of the third conjugate at a partially
accessible site with a neutral environment (HC-A114C)
was in between the other two and showed both mecha-
nisms. The stability of these variants corresponded with
their in vivo activity with the more stable conjugate show-
ing greater in vivo efficacy in mouse xenograft models
compared to the least stable conjugate. Other site-specific
conjugation methods such as use of transglutaminase have
also shown that conjugation site has an impact on ADC
stability and pharmacokinetics (44).
Conjugation can also impact tissue distribution of the
antibody and several studies have shown a trend towards
slightly increased hepatic uptake of ADCs (29,30,42). This
was seen with auristatin (29,42) and calicheamicin conjugates
(30). In contrast, the maytansinoids conjugated to the anti-
body through lysine residues (e.g. Kadcyla®, SAR3419,
IMGN901) showed tissue distribution profiles similar to the
naked antibody (45,46).
For auristatin conjugates, tissue distribution studies have
been conducted using the protease cleavable MC-vc-PAB-
MMAE linker with different drug loads (DAR 3.1 vs. DAR
1.7) and different conjugation methods (reduced interchain
disulfides vs. site specific conjugation through engineered cys-
teines) (29). Since increased hepatic uptake was seen with
conjugates with lower drug loads as well as different conjuga-
tion methods compared to the naked antibody, one proposed
hypothesis was that higher hydrophobicity of the drug conju-
gates compared to the naked antibody leads to a greater
clearance by the reticuloendothelial system (29). A recent
study by Seattle Genetics (47) to explore increased ADC
clearance with higher drug loading seen for the MC-vc-
auristatin linkers showed a correlation between hydrophobic-
ity and plasma clearance. The rapid plasma clearance with
higher drug loading (DAR of 8) seen with MC-vc-MMAF
linker (more hydrophobic), was slightly less pronounced with
MC-MMAF (slightly less hydrophobic) and was not seen with
a novel auristatin T-based drug linker (AT-GLu-MDpr)
which was designed to minimize hydrophobicity. In addition,
the AT-Glu-MDpr linked conjugate with high drug load
showed similar hepatic uptake as its parent antibody in a
perfused liver system. They also showed that full reduction
of the interchain disulfides of an antibody, without any drugs
attached to it, did not increase clearance of the antibody. This
study indicates that increased clearance and hepatic uptake
could be attributed to the intrinsic hydrophobicity of the drug
linker as hypothesized by several groups (29,31), and not due
to destabilization of the antibody structure due to reduction of
the interchain disulfides. Additional studies with different
antibodies as well as in vivo tissue distribution studies are
needed to confirm these interesting findings.
PRECLINICAL PK STRATEGY TO EVALUATE ADCS
At the preclinical stage, it is important to understand the
pharmacokinetics of an ADC in conjunction with its in vitro
and in vivo activity to gain insights into its mechanism of action
and help optimize and select the right ADC. ADC PK is
usually characterized in non-clinical species used for efficacy
and safety studies. The choice of the species for these studies
usually faces similar challenges as with the naked antibody in
terms of appropriate antigen binding i.e., when some species
may be a non-binding species. However, the non-antigen
dependent process should be similar in binding or non-
binding species. To adequately characterize the PK of an
ADC, it is critical to have the appropriate tools. As discussed
previously, there have been great advances in the types of
analytical methods tomeasure the different components of the
ADCs like the total antibody, conjugated and unconjugated
drug, DAR distribution, catabolites andmetabolites in various
matrices such as plasma, bile, and tissues from in vitro or in vivo
studies depending on the different stages of drug development
(11–13). Additional work is still needed to better understand
the best analytes to use for exposure-response correlations and
to better understand in vitro-in vivo correlations as well as cross-
species correlations.
Types of studies that can be done preclinically to charac-
terize the PK of ADCs include the following:
i. In vitro stability studies in plasma from different species to
understand linker stability as well as mechanisms of
deconjugation across species.
ii. In vitro catabolism studies to determine the types of
catabolites/metabolites formed and whether they have
any activity in in-vitro cell potency assays.
iii. In vivo PK and exposure of the various analytes in the
efficacy and toxicity species to characterize the PK, de-
termine PK drivers of efficacy/toxicity, establish in vitro--
in vivo correlations of stability and mechanisms of
deconjugation/catabolism.
iv. Biodistribution studies to look for tumor and normal
tissue uptake (specific or non-specific), and in vivo catabo-
lite profiles in various tissues, including understanding
any contribution of catabolites to any bystander effects.
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v. In vitro potency, CYP, and transporter profiling of the
cytotoxic drug to evaluate the risk of possible drug-drug
interactions in the clinic.
vi. Utilize in vivo exposure data at the efficacious and toxic
doses to estimate therapeutic index.
vii. Prediction of human PK to estimate efficacious dose and
schedule in patients.
In addition to studies to characterize the PK of ADCs, it is
also important to integrate PK, efficacy and toxicity data to
answer the key question on exposure-response relationships
and translation from preclinical species to patients. Model
based approaches can be used to integrate this data and
further our mechanistic understanding of the pharmacology.
Depending on the stage of development, different questions
become important (e.g., questions on target selection, anti-
body affinity, linker stability, E-R relationship) and the type of
model employed will depend on the type of question that
needs to be addressed. For example: early on in development,
systems pharmacology models can be used to enable target
selection, whereas classic PKPD models can be used later on
to understand exposure-response relationships as well as trans-
lational PKPD to predict human PK as well as efficacious dose
and dose regimens in patients. The modeling of ADC PK is
complicated due to the its multiple elimination pathways
including deconjugation and catabolism, as well as multiple
analytes with their distinct PK properties (conjugated anti-
body with multiple DAR species, unconjugated drug, uncon-
jugated antibody, etc.). Tremendous efforts are ongoing in
developing PK/PD models to guide the development of
ADCs. Some of the models that have been proposed include
semi-mechanistic PKmodels using a series of transit compart-
ments to describe the deconjugation process from higher to
lower DAR species (48,49), simplified models with a one-step
deconjugation process (48,50), target-mediated drug disposi-
tion models (51), and multi-scale mechanistic PK/PD models
(52,53). A key limitation for the use of some of these models is
the availability of appropriate data, or tools to obtain that
information. However, as more clinical data becomes avail-
able and tools to obtain these types of data improve, sophis-
ticated models can be developed and applied to expand our
understanding of the key analytes that correlate with efficacy
and safety.
CONCLUSION
The ADC field is rapidly expanding with many molecules at
various stages of development. With limited clinic data on a
small number of ADCs, the guidelines and strategies for
developing these molecules are still evolving. This review has
highlighted several areas where PK of an ADC makes an
impact on its activity. There have been huge strides in this
field, especially with new linker technology, site-specific con-
jugation techniques to create more homogenous ADCs, as
well as tremendous advances in novel bionalytical tools to
measure PK of various analytes and methods to integrate
the available PKPD information. Nevertheless, many ques-
tions still remain on PK drivers of efficacy and toxicity, opti-
mal design features of an ADC, translation of PKPD from
non-clinical species to patients, and optimal doses and dosing
regimens in the clinic. As more clinical data becomes available
and our understanding of the PK of ADCs with different types
of toxins, linkers and antibody formats improves, we can
tackle some of these outstanding questions.
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